Physician profile
Chituru Adele
NPI 1477500734
$2,276.74
in general payments reported to CMS, 2019-2025
24 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $190 · 2021: $573 · 2022: $395 · 2023: $480 · 2024: $246 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $278.11 | 2021-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $226.01 | 2019-2023 | |
| Pfizer INC. | $225.34 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $186.47 | 2020-2023 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $165.98 | 2020-2022 | |
| Abiomed | $162.77 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $151.30 | 2019-2024 | Eliquis, Camzyos |
| Cvrx, INC. | $131.64 | 2023 | Barostim Neo System |
| Amgen INC. | $104.09 | 2020-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $94.37 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $73.91 | 2022-2024 | Farxiga, Andexxa |
| Merck Sharp & Dohme LLC | $62.93 | 2022-2025 | Verquvo |
| Amarin Pharma, INC. | $59.40 | 2020-2021 | |
| Esperion Therapeutics, INC. | $57.98 | 2021 | |
| Boston Scientific Corporation | $55.37 | 2024-2025 | Bodyguardian, Varithena Administration Pack |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $49.00 | 2024-2025 | |
| Abbott Laboratories | $47.94 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.27 | 2021-2023 | Jardiance |
| Inari Medical, INC. | $33.88 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Edwards Lifesciences Corporation | $14.64 | 2020 | |
| Impulse Dynamics (USA) INC. | $14.31 | 2023 | Optimizer |
| Baxter Healthcare | $13.48 | 2025 | |
| Medtronic Vascular, INC. | $13.10 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chituru Adele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.